您的位置: 首页 > 农业专利 > 详情页

Identification of surface-associated antigens for tumor diagnosis and treatment
专利权人:
ガニュメート・ファーマシューティカルズ・アクチェンゲゼルシャフト
发明人:
テューレツィ,エツレム,サヒン,ウグール,シュナイダー,サンドラ,ハーフテンベイン、ゲルド,シュリューター,フェルカー,ウーゼナー,ディルク,ティール,フィリップ,ミカエル コスロウスキー,テューレツィ,エツレム,サヒン,ウグール,シュナイダー,サンドラ,シュリューター,フェルカー,ウーゼナー,ディルク,ティール,フィリップ
申请号:
JP2016086914
公开号:
JP6434444B2
申请日:
2016.04.25
申请国别(地区):
JP
年份:
2018
代理人:
摘要:
Composition comprises a substance which inhibits the expression or activity of a tumor-associated antigen, where the antigen has a sequence coded by a nucleic acid with specifically defined sequence. Composition comprises a substance (S1) which inhibits the expression or activity of a tumor-associated antigen (A1), where (A1) has a sequence coded by: a nucleic acid (I) with one of 29 specifically defined sequences given in the specification (SEQ ID 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 69, 71, 73, 75, 79, 80, 85, 87, 102, 104, 106, 108, 110 or 112); a nucleic acid (II) hybridizing to (I); a nucleic acid (III) degenerate with respect to (I) or (II); or a nucleic acid (IV) complementary to (I), (II) or (III). Independent claims are also included for the following: (1) composition comprising a substance (S2) with tumor-inhibiting activity selective for cells which exhibit an expression (optionally abmormal) of (A1); (2) composition containing a substance (S3) increasing the quantity of complexes between a human leukocyte antigen (HLA) and (A1) or its fragment; (3) diagnosis (M1) of diseases characterized by the expression or abnormal expression of tumor-associated antigens comprising the detection, in a biological sample isolated from a patient, of (I) or its fragment, (A1) or its fragment, (Ab) or its fragment, or cytotoxic or helper-T-lymphocytes specific for (A1) or its fragment; (4) treatment of diseases characterized by the expression or abnormal expression of tumor-associated antigens comprising removal of a patient sample with immunoreactive cells, contacting the sample with (C1) under conditions favoring the production of cytolytic or cytokine-releasing T-cells against (A1), and importing the cytolytic or cytokine-releasing T-cells into the patient in a quantity sufficient to promote lysis of cells expressing (A1); (5) treatment (M2) of diseases characterized by the expression or abnormal expression of tumor-associated antigens comprising ident
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充